



## Request for Proposal

### **AMP T2D RFP 16: New functional data generation for validation of genes or variants for diabetes and complications**

**Request:** The Foundation for NIH and AMP T2D Steering Committee is requesting short proposals covering the objectives described below for development and expansion of the Type 2 Diabetes Knowledge Portal in 2019-2020.

**Issued by:** The Foundation for the National Institutes of Health (FNIH) Division of Research Partnerships **on March 11, 2019.**

#### **Objectives:**

1. Discriminating between and prioritizing potential causal variants or genes in risk loci or credible sets by:
  - a. Developing preliminary functional annotation data to support strength of evidence for candidate genes for diabetes and complications (cardiovascular, obesity, kidney, liver function, retinopathy, glycemic traits); **and/or**
  - b. Generating mechanistic hypothesis for causal genes from cell-based genome-wide functional or perturbation studies (e.g. RNA-Seq, ATAC-Seq, CHIP-Seq, others); **and/or**
  - c. Developing and employing novel tools such as CRISPR tiling to combine with readout such as RNA-Seq to enable prioritizing potential causal variants or genes.

#### **Deliverables:**

1. Description of how understanding of disease causal gene or variant function has been advanced.
2. Report on experimental findings including access to experimental data.
3. Proposal on how this data might be integrated into the knowledge portal in the future.
4. Plan for future publications or follow up research activities.
5. Description of where novel tools or data have been deposited for public availability.
6. Proposal on how results will be made publicly accessible.

**Response to Proposal:** The proposals should address the sections outlined below and not exceed 5 pages in a 10 pt Arial font (not including the draft budget and description of investigative team). Please send completed proposals to Tania Kamphaus ([tkamphaus@fnih.org](mailto:tkamphaus@fnih.org)) and Sidra Iqbal ([siqbal@fnih.org](mailto:siqbal@fnih.org)) by **April 25, 2019**.

1. A description of the organization's approach to addressing the objectives and proposed deliverables.
2. A timeline for completing each milestone.
3. A draft budget and justification.
4. Brief description of the investigating team and their qualifications (NIH biosketch ok)
5. Note: If using non-human model, please justify model relevance to human genetics and function.

**Expectations:**

1. The applicants are expected to deliver the listed milestones by their due dates.
2. All data must be made publicly available on the listed due date, unless explicitly stated otherwise.
3. The deliverables must be met by **April 30, 2020** for project completion. *The Steering Committee will consider support for follow up work. If applicable, please supply an outline for extension. Extensions will be considered pending successful review and availability of resources.*

**Application Process:** The investigators can expect to meet with the AMP T2D Steering Committee by teleconference prior to finalizing deliverables. The purpose of the meeting is to allow for appropriate discussion of possible next steps as well as provide the opportunity for the respondent(s) to ask questions of the multi-stakeholder oversight group.

**Disclaimers:** The FNIH AMP T2D consortium reserves the right to suspend or terminate funding depending on demonstrable progression of the effort. The T2D AMP Steering Committee may choose to fund all or some of the given proposal.

**Final Proposal Responses:** Due **April 25, 2019**.

**For More Information:** Please contact Dr. Tania Kamphaus at [tkamphaus@fnih.org](mailto:tkamphaus@fnih.org) or Sidra Iqbal at [siqbal@fnih.org](mailto:siqbal@fnih.org). Feel free to ask questions to enable preparation of your responses.

**Eligibility:** Any organization from the private and public sector is eligible to apply as long the requirements below are met. It is acceptable for more than one organization to collaborate and submit a joint response.

**Target Selection Date:** **April 30, 2019**

**Target Start Date:** **April 30, 2019**

**About the AMP T2D Program:**

The Accelerating Medicines Partnership (AMP) Type 2 Diabetes (T2D) program is a precompetitive partnership among government (NIH), industry (Janssen, Eli Lilly, Merck, Pfizer, and Sanofi) and nonprofit organizations (ADA and JDRF) that focuses on leveraging human genetics studies in T2D and related complications to discover and validate novel targets. This multisector partnership is managed by the Foundation for the NIH. The combined public and private sector funding support for the five-year endeavor is \$58.4 million dollars. The AMP provides participating organizations the chance to collaborate on research on a scale that would not be possible for individual companies. Moreover, through close coordination the AMP provides not only access to data and analyses but also the ability to leverage substantial scientific and financial resources provided in partnership with National Institutes of Health and academic researchers. For more information, please go to:

<https://fnih.org/what-we-do/programs/amp-t2d-project>

<https://www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes>

<http://www.type2diabetesgenetics.org/>